Decision on Covaxin emergency authorisation expected by Sept: MEA

Advertisement

The World Health Organisation has said the agency expects to make a decision next month on an emergency authorisation for the Indian-made COVID-19 vaccine….reports Asian Lite News

The Ministry of External Affairs (MEA) on Thursday said a decision on emergency authorisation for the Covaxin Covid-19 vaccine made by Bharat Biotech is expected to be announced by September as the World Health Organisation (WHO) takes 6-8 weeks to grant the emergency use listing.

In a media briefing, MEA spokesperson Arindam Bagchi said, “Covaxin submitted its application on July 9 so we are expecting a response by September as it takes 6-8 weeks for the WHO to grant the EUL.”

External Affairs Minister S Jaishankar had made a similar statement at the CII annual event.

The World Health Organisation has said the agency expects to make a decision next month on an emergency authorisation for the Indian-made COVID-19 vaccine.

Last week, Bharat Biotech’s Covaxin received a Good Manufacturing Practices (GMP) compliance certificate from Hungary. The certificate of GMP is now listed on the EudraGMDP database which is the collection of records of the European Community of manufacturing authorisations and certificates of good manufacturing practice, Bharat Biotech said.

Asked about the actions taken by the government on easing Covid travel restrictions, the MEA Spokesperson said, “There are many countries where Covid restrictions are there. Not just students, other people who would like to travel are facing problems. As I have said earlier, we attach high importance to ensuring ease of these restrictions whether they live abroad for education or employment. We have been actively taking up this matter at various levels including at the ministerial levels with all of the countries. I am happy to see some forward movements with some of the countries. MEA will continue to attach high priority to this issue.” (India News Network)

ALSO READ: No compromise on Covaxin quality, says Bharat Biotech

ALSO READ: Nod for proposal to study mixing of Covid-19 vaccine doses